{
  "docId": "019de074-dee8-7497-a5f7-ae2745d7f9f6",
  "docSlug": "87d7e2eb7c56e30923dbf29903df5034",
  "documentTitle": "Compass Therapeutics | Investor Presentation Deck | 40 slides",
  "authorId": "compass-therapeutics",
  "authorName": "Compass Therapeutics",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-05-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 39,
  "pageCount": 40,
  "prevPage": 38,
  "nextPage": 40,
  "slideType": "executive_summary",
  "function": "summarize",
  "density": "dense",
  "nDataPoints": 5,
  "notes": null,
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de074-dee8-7497-a5f7-ae2745d7f9f6/39",
  "deckHref": "/decks/019de074-dee8-7497-a5f7-ae2745d7f9f6",
  "deckJsonHref": "/decks/019de074-dee8-7497-a5f7-ae2745d7f9f6.json",
  "deckAnchorHref": "/decks/019de074-dee8-7497-a5f7-ae2745d7f9f6#slide-39",
  "components": [
    {
      "bbox": {
        "h": 0.2,
        "w": 0.9,
        "x": 0.05,
        "y": 0.7
      },
      "kind": "list",
      "text": "CTX-8371 Next generation PD-1 x PD-L1 bispecific antibody. Discovered with our StitchMabs™ screening platform. Superior activity to commercial PD-1 and PD-L1 inhibitors in preclinical studies. Unique MOA – enhances T-cell activation.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "10da642e-f09f-4beb-971d-470ac411205e",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.9,
        "x": 0.05,
        "y": 0.185
      },
      "kind": "list",
      "text": "CTX-009 Novel DLL4 x VEGF-A bispecific antibody with both combination and monotherapy activity. Phase 1: Dose response established. BTC Phase 2 results: 24 patients: 37.5% ORR (2L/3L), 63.6% (2L), median PFS 9.4 months, OS 12.5 months.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5d1c8f1c-8f8d-4169-b6be-84ffd3cc07bf",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.2,
        "w": 0.9,
        "x": 0.05,
        "y": 0.45
      },
      "kind": "list",
      "text": "CTX-471 Potential best-in-class CD137 agonist antibody with monotherapy activity. Phase 1 monotherapy study fully enrolled. 4 partial responses (PRs) in post PD-1 population. CTX-471 in combination with KEYTRUDA® study was initiated in 4Q 2022.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "86689ac2-3a5b-404a-8b63-2221800372c6",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.29,
        "x": 0.035,
        "y": 0.08
      },
      "kind": "title",
      "text": "Program Summary",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c269d6c1-0a4c-4654-8486-7e5c6c738874",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Executive summary",
      "slug": "executive-summary",
      "agent": null,
      "layer": "slide",
      "matchId": "0e5d3303-fe04-44fd-8d89-bb0c3807586c",
      "evidence": "list/bullet: CTX-471 Potential best-in-class CD137 agonist antibody with monotherapy activity. Phase 1 monotherapy study fully enrolled. 4 partial responses (PRs) in post PD-1 population.",
      "confidence": 0.9
    }
  ],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}